TSHR and Graves disease: However, in a mouse model that spontaneously develops pathogenic TSHR antibodies (126), injecting TSHR A-subunit protein failed to divert the autoantibody response to a non-pathogenic form, highlighting critical differences between induced and spontaneous Graves’ disease models, with implications for potential immunotherapy in humans (127).